Epitope Diagnostics

Epitope Diagnostics is a privately held, established player in the specialized immunoassay diagnostics market, focusing on niche areas with high unmet needs. The company leverages three core technology platforms—chemiluminescence (CLIA), automated ELISA, and its patented EPITUUB® rapid test device—to serve global clinical and research laboratories. With a history of innovation, including launching the world's first commercial Fetuin-A ELISA and a patented fecal sample test device, EDI targets a diverse range of disease areas from cancer to infectious diseases. Its certified manufacturing and regulatory clearances position it as a reliable supplier in the global IVD community.

Three core platforms: 1) Chemiluminescence Immunoassay (CLIA) for automated, sensitive testing (e.g., ECL100, ECL25). 2) ELISA (Enzyme-Linked Immunosorbent Assay) in manual and automated formats. 3) Patented EPITUUB® rapid test device, a self-contained, odorless platform for stool-based tests (US Patent 7,780,915), which is FDA-cleared and CLIA-waived.

EDI competes in the specialized niche immunoassay segment, distinct from high-volume routine testing dominated by giants like Roche and Abbott. Competitors include other focused immunoassay companies (e.g., Eagle Biosciences, R&D Systems) and diagnostic divisions of larger life science tools companies. Its patented rapid test platform provides differentiation in fecal sample testing.